ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > We might see new Lows this Year

<< Previous

Bullboard Posts

Next >>

Post by DavidKingCanadaon Jan 14, 2022 3:26pm

146 Views

Post# 34318566

We might see new Lows this Year

Get ready for some new Lows until they come up with some legit DEAL in place instead of all the mumbo jumbo they have been talking about for Years now. I wanted to sell yesterday at 0.16 CAD but waited because it might have gone higher but now we are way down to 0.135. Pathetic!

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing